Is Perspective Therapeutics Inc. (CATX) overvalued? · rev $2.2M
Perspective Therapeutics Inc. (CATX) is a medical devices company listed on US.
This page asks whether Perspective Therapeutics Inc. (CATX) looks expensive on cached numbers — not a short thesis.
Latest reported CATX revenue for 2023-09-30 was $2.2M. Net income was -$10.4M. Revenue was up 4.6% from 2023-06-30 to 2023-09-30. CATX currently screens at market cap $280.6M.
CATX currently screens at market cap $280.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CATX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CATX stock page for the full model, not this heading.
Not investment advice.